ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2026
Salvage Treatment Options for Posttransplant Relapse in Children with Early/Very Early Relapse of Acute Lymphoblastic Leukemia: A Single-Center Experience
Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate salvage treatment options for posttransplant relapse in children with early/very early relapse of acute lymphoblastic leukemia (ALL). Forty consecutive high-risk ALL cases were divided into two groups based on the salvage treatment for posttransplant relapse: Group 1 (n=9) received purine nucleoside analogs (fludarabine/clofarabine-based regimens), while Group 2 (n=8) received targeted agents (blinatumomab, bortezomib, and chimeric antigen receptor T-cells). In Group 1, seven children received a fludarabine-based regimen and two received a clofarabine-based regimen. In Group 2, five children received bortezomib-based regimens, two received blinatumomab, and one received chimeric antigen receptor T-cells. Group 2 showed a significantly higher cumulative survival rate (75% vs. 22%) and lower grade 3 and 4 toxicity rates (13% vs. 66%) compared to Group 1 (p<0.05). Based on our limited data, targeted agents may constitute an effective treatment option and can be directly recommended for posttransplant relapse in children with high-risk ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.